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Heparan sulphate with no affinity for antithrombin III (ATIII) was observed to cause acceleration of the factor Xa:ATIII 
interaction by 1100-fold (k2, 7 × 107 M-l.min -1) and the prothrombinase:ATllI interaction by 2900-fold (k2, 2.5 x l0 T 
M-1 .min-1). Although igh-affinity heparan sulphate catalyzed higher acceleration and at lower concentration, i  natur- 
al mixtures of the two forms the activity of the no affinity form predominated. Heparan sulphate had no significant effect 
on the thrombin:ATIII interaction but inhibited its potentiation by heparin (Kd 0.3/~M). From the estimated concentra- 
tion of heparan sulphate on the endothelial cell surface it is proposed that the non-thrombogenic property of blood vessels 
is due to the acceleration of the factor Xa or prothrombinase:ATIIl interaction by the greater mass of surface-bound 
heparan sulphate rather than by the much smaller proportion of heparin-like molecules (with high affinity for antithromb- 
in III) which may be present. 
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1. INTRODUCTION 
It is well established that the serine protease in- 
hibitor, antithrombin III (ATIII) is important in 
the control of haemostasis and familial deficiency 
of ATII I  (blood levels less than about 50070 of nor- 
mal) is associated with recurrent thromboembolic 
disease [1,2]. However, the rate of interaction be- 
tween the inhibitor, at physiological concentra- 
tions, and the activated coagulation factors is 
substantially less than that which is characteristic 
for proteinase inhibitors [3]. The rate is ac- 
celerated, catalytically, by heparin [4] and it has 
been proposed that heparin-like molecules (i.e. 
with the property of tight binding to ATIII) 
located on the vascular endothelium are responsi- 
ble for the ATllI-dependent, non-thrombogenic 
properties of blood vessels [5]. Heparan sulphate 
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proteoglycans with this property have been 
isolated from aortic tissue [6] and from endothelial 
cell cultures [7]. In relationship to the total mass of 
sulphated glycosaminoglycans (GAGS) in such 
material the heparin-like material is present at very 
low concentrations (about 0.2°7o of the total) [8]. 
Although heparin is particularly effective in ac- 
celerating the protease:ATII I  interaction, other 
GAGS (e.g. dermatan sulphate) present within the 
vasculature have been found to possess this 
property but to a lesser degree [9,10]. These latter 
studies compared the potency of these GAGS to 
heparin and did not evaluate their potential to be 
involved in the non-thrombogenic property of 
blood vessels. In this present work, we have 
evaluated the potency of these GAGS, using a 
kinetic approach and propose that the ATIII- 
dependent, non-thrombogenic property of the 
vascular endothelium ay arise from the mass of 
surface-bound heparan sulphate rather than to the 
small proportion of heparan sulphate molecules 
with a high affinity for ATIII. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Human factor Xa, prothrombin and ATIII were prepared as 
described previously [11-13]. Human el-thrombin was kindly 
supplied by Dr J. Fenton, New York Dept of Health, Albany, 
USA. Pure heparan sulphate (SOJCOOH ratio, 1.68; an- 
ticoagulant activity, 5 U/mg) and dermatan sulphate 
(SOjCOOH, 1.19; anticoagulant activity, 8 U/mg) prepared 
from porcine intestinal mucosa were obtained from 
Mediolanum Farmaceutici, Milan, Italy and gave single bands 
upon electrophoresis. Chondroitin sulphate A (whale cartilage) 
and chondroitin sulphate C (shark cartilage) were obtained 
from Sigma, Poole, England. Standard heparin (average 
molecular mass 15 kDa) and low molecular mass heparin 
(Fraxiparine ® , 4.2 kDa) were obtained from Leo 
Laboratories, England and Choay Laboratories, France, 
respectively. Washed platelets were prepared as previously 
described [14]. Fractionation of heparan sulphate and heparin 
over ATIII immobilized on concanavalin A (conA) Sepharose 
were made as described previously [15]. 
2.2. Determination o f  the rate of  inhibition of  factor Xa, 
platelet-bound factor Xa (prothrombinase) and thrombin 
by A Ti l l  in the presence of  various GAGS 
This was made under pseudo first-order conditions as 
described previously [14,16]. 
2.3. Measurement of  antiheparin activity 
The inhibition, by increasing the concentration f GAGS, of 
the rate of interaction between ATIII and thrombin in the 
presence of heparin was measured in mixtures containing 
25 nM ATIII, 1.5 nM thrombin, 3.3 nM heparin (with high af- 
finity for ATIII) and 0.2 mM chromogenic substrate $2238 
(KabiVitrum, England) in 0.1 M triethanolamine/HC1 (pH 
7.8)/0.1 M NaCI containing 0.1070 (w/v) poly(ethylene glycol) 
6000 at 37°C. The change in absorbance was followed at timed 
intervals in an Abbott bichromatic analyzer using 380/450 nm 
filter and first-order ate constants calculated from semi- 
logarithmic plots of absorbance against time, as described 
previously [16]. 
3. RESULTS 
3.1. Fractionation of heparan sulphate upon 
immobilized A TIII 
Heparan sulphate was chromatographed over 
AT I I I  immobilized upon ConA-Sepharose [15] 
and fractions pooled separately and concentrated 
to represent no affinity (NA), low-affinity (LA) 
and high-affinity (HA) fractions, respectively. The 
yield of each was measured and found to be, as a 
percentage Of the total, 97.4°7o for NA, 2.0% for 
LA and 0.6% for HA. Pooling of fractions after 
chromatography of a similar amount of heparin 
gave the following percentages: 45% (NA), 33% 
(LA) and 23% (HA). Very little heparan sulphate 
was bound, therefore, to a column capable of 
binding substantial amounts of low- and high- 
affinity heparin. 
3.2. Acceleration of the rate of inhibition of 
factor Xa and prothrombinase by A Till in 
the presence of various GAGS 
Neither chondroitin sulphate A nor chondroitin 
sulphate C showed any significant effect on the 
rate of inhibition of free factor Xa or 
prothrombinase-bound factor Xa by ATI I I .  Both 
heparan sulphate with no affinity and dermatan 
sulphate were able to accelerate these reactions 
(fig. 1). With free factor Xa the maximum observed 
rate at 140 ~M heparan sulphate was equal to a 
second-order rate constant of 7 × 10 7 M -1 .min -1 
or 1100-fold increase over the basal rate of 6.3 x 
10 4 M -1 -min -1 in the absence of GAGS [14]. The 
maximum rate of inhibition of factor Xa in the 
prothrombinase complex was equal to a second- 
order rate constant of 2.5 × 107 M-a .min  -1 or 
2900-fold increase over a basal rate of 0.85 x 
104 M - l -min  -1 [13]. High-affinity heparan 
sulphate was a potent activator of the factor 
Xa : ATI I I  interaction (6500-fold, 4.1 x 
108 M-~.min  -1) but in the natural mixture of 
forms, the activity of heparan sulphate with no af- 
finity tended to predominate and an acceleration 
of 1000-fold was observed. 
Dermatan sulphate was somewhat less potent 
but reached a maximum rate with free factor Xa 
equal to a 580-fold acceleration (3.6 × 
107 M-~.min -~) and 850-fold of the prothrom- 
binase:ATI I I  interaction (7.5 x 10 6 M -~.min-1). 
The maximal fold acceleration by a low molecular 
mass heparin (high affinity for ATI I I ,  Mr 4.2 kDa) 
was 660-fold (4 x 107 M -~- min -1) with free factor 
Xa and 1930-fold (1.7 x 10 7 M -1.  min -1) with pro- 
thrombinase. 
3.3. Influence of GAGS on the thrombin:ATIII 
interaction 
None of the GAGS, apart from the HA heparan 
sulphate, caused significant acceleration of the 
thrombin : ATI I I  interaction (< 30-fold maximum 
acceleration) as we have previously observed for 
non-heparin GAGS [16]. However, all caused in- 
hibition of the rate of interaction between throm- 
bin and ATII1 occurring in the presence of heparin 
(fig.2). This anti-heparin activity has been iden- 
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Fig. 1. Effect of GAGS on the rate constant for the inhibition of free and platelet-bound factor Xa (prothrombinase) by ATIII. The 
second-order rate constant is plotted against molar concentration f GAGS on a double logarithmic scale. The second-order rate 
constant was calculated from the rate of inhibition of 3.6 nM factor Xa by 30 nM ATIII in 0.05 M Tris-HCl (pH 7.4)/0.1 M 
NaC1/5 mM CaClz/0.1% poly(ethylene glycol) 6000 at 37°C [14]. The molecular mass values for heparan sulphate and dermatan 
sulphate were taken as 25 kDa. (n) NA heparan sulphate, free factor Xa; (m) NA heparan sulphate, prothrombinase; (©) HA 
heparan sulphate, free factor Xa; (e) natural mixture of heparan sulphate, free factor Xa; (A) dermatan sulphate, free factor Xa; 
(A) dermatan sulphate, prothrombinase; (0) heparin (4.2 kDa), free factor Xa; (*) heparin (4.2 kDa), prothrombinase; (-~) mixture 
of heparan sulphate, dermatan sulphate, CSA and CSC (see text). 
tified by us previously as a property of sulphated 
polysaccharides and is due to their ability to bind 
thrombin [12]. The binding affinity of each GAGS 
for thrombin was estimated by plotting the inverse 
of the observed rate against their concentration 
[12] and these were calculated as 0.3/~M heparan 
sulphate, 4/~M dermatan sulphate, 14/~M chon- 
droitin sulphate A, and 6 FM chondroitin sulphate 
C. 
Fig.2. Antiheparin effect of GAGS. The effect was measured of 
increasing concentrations of GAGS upon the rate of the ATIII 
(25 nM): thrombin (1.5 nM) interaction in the presence of 
3.3 nM HA heparin. (m) Heparan sulphate; (A) dermatan 
sulphate; (,) chondroitin sulphate A; (e) chondroitin sulphate 
C. 
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4. DISCUSSION 
From the evidence presented here we propose 
that, although heparin-like molecules may play a 
part in the ATII I -dependent, non-thrombogenic 
properties of blood vessels, other GAGS, by virtue 
of their greater mass, may constitute the principal 
catalyst. 
The concentration of proteoglycans on intact 
native endothelium has been estimated, by la- 
belling with 35SO4 and also by X-ray microanalysis 
to be about 10 -12 mol polysaccharide chain per 
cm 2 or about 0.2 mM assuming the thickness of 
the glycocalyx to be 100 nm [17,18]. Of this con- 
centration about half is heparan sulphate. 
Although heparan sulphate with no affinity for 
AT I I I  will be available for binding other plasma 
proteins, e.g. lipoprotein lipase, its concentration 
is 10-100 times higher than that which we ob- 
served here to cause maximal acceleration of the 
factor Xa (prothrombinase):ATI I I  interaction. 
This degree of acceleration was similar to the maxi- 
mum achieved by a low molecular mass, high- 
affinity heparin with clinically proven antithrom- 
botic properties [19]. Furthermore, when the reac- 
tion is accelerated by the natural mixture of 
heparan sulphate forms then the activity of 
heparan sulphate with no affinity for ATI I I  
predominates. As also shown in fig. 1, when a mix- 
ture containing 30/zM heparan sulphate (natural 
mixture) and 10/zM of each chondroitin sulphates 
A and C and dermatan sulphate, respectively, was 
tested, the rate observed was similar to that seen 
with heparan sulphate alone. 
From our observations we also propose that 
catalysis of the thrombin : ATI I I  interaction by any 
heparin-like species on the endothelium will be in- 
hibited by the anti-heparin properties of other 
GAGS. We have shown previously that the an- 
tiheparin property of other sulphated polysac- 
charides, is due to abortive binding to thrombin 
interfering with the mechanism of heparin catalysis 
[12] (which requires coincident binding of ATI I I  
and thrombin to the same heparin molecule). 
Thrombin activity will be controlled in vivo 
presumably, by sequestering onto high-affinity 
sites on which it is not active, e.g. throm- 
bomodulin or by clearance through the RE system. 
The control of factor Xa (prothrombinase) may, 
therefore, be a central feature in the ATI I I -  
dependent modulation of coagulation, coinciding 
with the findings of Bauer et al. [20] who observed 
that in plasma samples from ATIII-deficient pa- 
tients there was evidence of a reduction in the con- 
trol of factor Xa activity rather than of thrombin 
activity. 
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